Clinical trials: Toripalimab
Locally Advanced Esophageal Squamous Cell Carcinoma
Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)
Although definitive chemoradiotherapy (CRT) is the standard treatment option for unresectable locally advanced esophageal cancer, elderly patients tolerate intravenous concurrent CRT less well with age and comorbidities.
- Trial name
- EC-CRT-007 (NCT06187597)
- Testing
- S-1, Toripalimab, Intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Sun Yat-sen University
Unresectable Hepatocellular Cancer, Portal Vein Tumor Thrombus
Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus
This study aims to evaluate the efficacy and safety of sorafenib plus toripalimab for unresectable hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT).
- Trial name
- STUHCCPVTT (NCT04069949)
- Testing
- sorafenib; toripalimab
- Volunteers
- 39 people
- Sponsor
- Sichuan University
Triple-negative Breast Cancer
A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.
To evaluate the clinical efficacy and safety of oral all-trans retinoic acid in combination with toripalimab in patients with locally advanced, recurrent, or metastatic triple-negative breast cancer who had failed second-line and…
- Trial name
- NCT06371274
- Testing
- ATRA, Toripalimab
- Where
- China
- Volunteers
- 29 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Non-Small Cell Lung Cancer
Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC
This is a prospective, multicenter, single-arm Phase II investigator-initiated trial evaluating neoadjuvant toripalimab plus sacituzumab tirumotecan (SKB264) in treatment-naive adults with resectable or potentially resectable…
- Trial name
- NCT07819578
- Testing
- Toripalimab, Sacituzumab Tirumotecan (SKB264)
- Volunteers
- 30 people
- Sponsor
- Shaodong Hong
Locally Advanced Rectal Cancer
Short-course Radiotherapy Based TNT Combined With PD-1 Inhibitor for Locally Advanced Rectal Cancer
TORCH is a prospective, multicentre, randomized phase II trial. 130 LARC (T3-4/N+M0, distance from anal verge ≤12cm) patients will be treated with total neoadjuvant therapy (TNT) and assigned to Group A and Group B.
- Trial name
- TORCH (NCT04518280)
- Testing
- PD-1 antibody, Capecitabine, Oxaliplatin
- Where
- 3 sites in China
- Volunteers
- 130 people
- Sponsor
- Fudan University
Nasopharyngeal Cancer
Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT
Nasopharyngeal carcinoma is biologically different from traditional head and neck squamous cell carcinoma. The mainstay treatment for locally advanced nasopharyngeal carcinoma is cisplatin-based concurrent chemoradiation.
- Trial name
- NCT05628922
- Testing
- Toripalimab, Induction chemotherapy and concurrent chemoradiation
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Fudan University
Cervical Cancer
Niraparib Combined With Brivanib or Toripalimab in Patients With Cervical Cancer
A Clinical Proof-of-concept Study Evaluating Efficacy and Safety of ZL-2306 (Niraparib) Combined With Brivanib or Toripalimab in Patients With Metastatic, Recurrent, and Persistent Cervical Cancer
- Trial name
- CQGOG0101 (NCT04395612)
- Testing
- niraparib combined with brivanib, niraparib combined with toripalimab
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Chongqing University Cancer Hospital
Small Cell Lung Carcinoma
Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer
To evaluates the effectiveness and safety of Surufatinib combined with chemotherapy plus Toripalimab or not for the first-line treatment of SCLC, and maintenance therapy are Surufatinib combined with Toripalimab or not.
- Trial name
- NCT04996771
- Testing
- Surufatinib,Etoposide,Cisplatin,Toripalimab, Surufatinib,Etoposide,Cisplatin
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Sun Yat-sen University
Solid Tumor, Neoplasms
A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerance, Dose-Limiting Toxicity (DLT), Maximum tolerated dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of ES102 (OX40 agonist) in combination with JS001 (anti-PD-1…
- Conditions
- Solid Tumor, Neoplasms, Malignant Tumor
- Trial name
- NCT04991506
- Testing
- ES102, JS001
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Elpiscience Biopharma, Ltd.
Nasopharangeal Cancer, Recurrent Nasopharynx Carcinoma
PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC
This phase II randomized trial evaluates PD-1 inhibitor plus chemotherapy followed by immediate versus selective re-irradiation in locally advanced recurrent nasopharyngeal carcinoma.
- Trial name
- NCT07332247
- Testing
- Selective re-irradiation, Immediate re-irradiation
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Sun Yat-sen University
Advanced Solid Tumor
A Phase I/II Study of TJ004309 for Advanced Solid Tumor
This study is a phase I/II study of single drug TJ004309 and Toripalimab combine treatment for Advanced solid tumor. This study include two stages. First stage is dose escalation and second stage is dose extension.
- Trial name
- NCT04322006
- Testing
- TJ004309, Toripalimab
- Where
- 23 sites in China
- Volunteers
- 225 people
- Sponsor
- TJ Biopharma Co., Ltd.
Advanced Hepatocellular Carcinoma (HCC)
A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)
This is an open-label, single-arm, national multicenter phase II clinical study to preliminarily observe and evaluate the efficacy and safety of Toripalimab combined with Bevacizumab as the first-line therapy for advanced HCC The…
- Trial name
- NCT04605796
- Testing
- Toripalimab combined with Bevacizumab
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
HCC, Therapy Adverse Effect
ICIs With and Without MWA in Advanced Hepatocellular Carcinoma
Immunotherapy has become the main treatment recommendation for HCC. MWA treatment induces peripheral immune response, which may enhance the effectiveness of immunotherapy for advanced HCC.
- Trial name
- IMI-aHCC (NCT06581497)
- Testing
- ICIs, ICIs+MWA
- Where
- China
- Volunteers
- 52 people
- Sponsor
- The First People's Hospital of Neijiang
Advanced Solid Tumor
A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours
Based on overall response rate (ORR) as assessed by the Independent Review Committee (IRC) against the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria for Solid Tumor Efficacy, To evaluate the efficacy of…
- Trial name
- NCT06873854
- Testing
- LM-108, Toripalimab
- Where
- China
- Volunteers
- 84 people
- Sponsor
- LaNova Medicines Limited
Advanced Biliary Tract Cancer
HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC
Hepatic arterial infusion chemotherapy (HAIC) deliver high concentration of chemotherapeutic agents directly to the liver tumor, was proved to be effective for intrahepatic and perihilar cholangiocarcinoma.
- Trial name
- NCT04217954
- Testing
- OXA, 5-FU and bevacizumab plus Toripalimab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Peking University
Esophageal Squamous Cell Carcinoma
Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma
This study aims to evaluate the efficacy and safety of neoadjuvant sacituzumab tirumotecan (SKB264/MK-2870) combined with toripalimab in patients with locally advanced, resectable esophageal squamous cell carcinoma (ESCC).
- Trial name
- NCT07823270
- Testing
- Sacituzumab tirumotecan, Toripalimab
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Hebei Medical University Fourth Hospital
Laryngeal Cancer, Hypopharynx Cancer
Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma
The aim of this study is to define whether combination of induction chemotherapy and PD-1 inhibitor (Toripalimab) improve the rate of larynx preservation, for patients with resectable laryngeal/hypopharyngeal carcinoma.
- Conditions
- Laryngeal Cancer, Hypopharynx Cancer, Laryngeal Neoplasms
- Trial name
- INSIGHT (NCT04995120)
- Testing
- chemotherapy TP regimen combined with Toripalimab
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Fudan University
Nasopharyngeal Cancinoma (NPC)
Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma
This phase II randomized trial compares the efficacy and safety of Toripalimab combined with three different platinum-based induction chemotherapy regimens, sequentially followed by standard concurrent chemoradiotherapy, for the…
- Trial name
- NCT07362979
- Testing
- GP plus Toripalimab Induction chemotherapy+CCRT, TP plus Toripalimab Induction chemotherapy+CCRT, TPC plus Toripalimab Induction chemotherapy+CCRT
- Where
- 4 sites in China
- Volunteers
- 243 people
- Sponsor
- Sun Yat-sen University
Advanced Melanoma, Metastatic Melanoma
Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma
This is a multi-center, open-label, phase 2 study evaluating the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with locally advanced or metastatic melanoma who have failed in routine systemic treatment.
- Trial name
- NCT03013101
- Testing
- humanized anti-PD-1 monoclonal antibody toripalimab
- Where
- 6 sites in China
- Volunteers
- 128 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Esophageal Carcinoma
Toripalimab Combined With Radiotherapy and S-1 for Older Patients With Esophageal Cancer
This trial aims to assess efficacy and safety of toripalimab combined with radiotherapy and S-1 followed by adjuvant toripalimab maintenance therapy for older patients with stage II-III esophageal cancer.
- Trial name
- Best-EEC (NCT06009705)
- Testing
- toripalimab
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Hebei Medical University Fourth Hospital